Company
Headquarters: Lund, Sweden
Employees: 175
kr3.30 Billion
SEK as of July 1, 2024
US$311.3 Million
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. It conducts research primarily in the fields of gastrointestinal and immune health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. The company provides dietary supplement, and food and beverage products in the form of capsules, tablets, chewable tablets, spheres, fast melt sticks, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. It sells its products approximately in 40 countries worldwide. Probi AB (publ) has a collaboration with àrebro University for research into exploration of novel, needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian female population. The company was founded in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
Top 1-year algo backtest: +227.67%
$10,000 in September 2023 would now be $32,767 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Probi AB has the following listings and related stock indices.
Stock: OMX: PROB wb_incandescent